Your doctor says methylene blue plus an SSRI means serotonin syndrome. A 45-year physician says that warning comes from high-dose surgical cases, not the low oral doses he actually uses. Steven Warren, a longevity medicine physician who spent 25 years running nursing homes and geriatric psychiatry, dug into all 51 published cases and found nearly every one was high-dose IV under anesthesia. He explains the dose that helps, the dose that harms, and why he tells patients to read the literature themselves.

⏱️ Chapters:
0:00 Introduction
0:24 The only doctor for an area the size of Rhode Island
1:48 Why he walked away from patients dying on 23 meds
2:51 The COVID brain fog that sent him back to methylene blue
4:26 What all 51 serotonin syndrome cases had in common
5:42 The Goldilocks dose that changes everything
6:56 Why no one will pay to study it
7:51 The 77-year-old who remembered 150 names
9:17 What he tells patients about the missing data
10:53 What your blue urine is actually telling you
12:21 Why medical school did not teach him everything
14:07 The peptide stacking that worries him most
16:46 The vitamin D mistake he keeps seeing
17:48 What he says to the doctors who dismiss longevity medicine
19:06 Take home messages

About this episode:
Steven Warren spent his first decade as the only physician across a rural Utah area the size of Rhode Island, then 25 years running 14 nursing homes and doing geriatric psychiatry before moving into longevity medicine. After COVID-19 sent waves of brain fog patients into his office, he returned to a tool he had used in ICUs and cardiovascular shock units decades earlier: methylene blue. When patients arrived warning him their other doctors said an SSRI plus methylene blue guarantees serotonin syndrome, he went to the literature and found 51 published cases, nearly all of them high-dose IV given under anesthesia during parathyroid or abdominal surgery, not the low oral doses he prescribes. He lays out what he calls the Goldilocks problem, that low doses do nothing, high doses cause the problems, and the benefit sits in a narrow window around five milligrams taken two or three times a day. He is candid that there are no randomized controlled trials, that the efficacy evidence is anecdotal, and that no one will fund studies on a compound that cannot be patented. The conversation widens into peptide stacking, vitamin D toxicity, supplement quality control, and his core message to colleagues, that medical school did not teach them everything and the obligation to keep reading never ends. It is a conversation about staying skeptical in both directions, of the warnings and of the hype.

🤝 Partner with me on the KevinMD platform:
With over three million monthly readers and half a million social media followers, I give you direct access to the doctors and patients who matter most. Let's work together to tell your story.

➡️ PARTNER WITH KEVINMD: https://kevinmd.com/influencer
➡️ SUBSCRIBE TO THE PODCAST: https://www.kevinmd.com/podcast
➡️ RECOMMENDED BY KEVINMD: https://www.kevinmd.com/recommended

#MethyleneBlue #LongevityMedicine #PhysicianVoice